Kei Ishibashi

Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site

Takayuki Ohkuri, Akemi Kosaka, Kei Ishibashi et al. · Cancer Immunology Immunotherapy · 2017 · 202 citations · Full text

Inflammation, Intratumoral Administration, Cytokine +12

Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy

Toshihiro Nagato, Takayuki Ohkuri, Kenzo Ohara et al. · Cancer Immunology Immunotherapy · 2017 · 158 citations · Full text

Lymphoid Neoplasia, Autoimmune Disease, Soluble Form +10

Etiology of Severe Sensorineural Hearing Loss in Children: Independent Impact of Congenital Cytomegalovirus Infection and<i>GJB2</i>Mutations

Hiroshi Ogawa, Tatsuo Suzutani, Yohko Baba et al. · The Journal of Infectious Diseases · 2007 · 121 citations · Full text

Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade

Kei Ishibashi, Tobias Haber, Ines Breuksch et al. · Oncotarget · 2017 · 55 citations · Full text

CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes

Akemi Kosaka, Kei Ishibashi, Toshihiro Nagato et al. · The Journal of Experimental Medicine · 2021 · 51 citations · Full text

Immunology, Immune Regulation, Immunoediting +20